Medical Policy and Coding Updates - February 2025
Premera's February 2025 update adds carpal tunnel release as a new surgical policy effective May 6, 2025, and changes IL-5 inhibitor and Dupixent asthma criteria, including the blood eosinophil count, which was lowered from 300 to 150 cells/mcL. It also moves Briumvi, Lemtrada, Ocrevus, Ocrevus Zunovo, Tyruko and Tysabri from the multiple sclerosis policy into a new Gene Therapies for Rare Diseases policy effective February 1, 2025, and removes site-of-service review from many infusion and biologic codes while keeping medical necessity and prior authorization review.